Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P10696
UPID:
PPBN_HUMAN
Alternative names:
ALP-1; Alkaline phosphatase Nagao isozyme; Alkaline phosphatase, placental-like; Germ cell alkaline phosphatase; Placental alkaline phosphatase-like
Alternative UPACC:
P10696; A8KAF2; Q16727; Q53S81; Q96CM1
Background:
Alkaline phosphatase, germ cell type (P10696), known by alternative names such as ALP-1, Alkaline phosphatase Nagao isozyme, and Placental alkaline phosphatase-like, plays a crucial role in hydrolyzing various phosphate compounds. This enzyme's activity is pivotal in numerous biological processes, including bone mineralization and the breakdown of phosphate esters, which are vital for cellular energy and signaling.
Therapeutic significance:
Understanding the role of Alkaline phosphatase, germ cell type, could open doors to potential therapeutic strategies. Its ability to hydrolyze phosphate compounds suggests its involvement in key physiological pathways, offering a promising avenue for the development of treatments targeting metabolic and bone diseases.